Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$474.16

-7.10 (-1.48%)

(As of 09/18/2024 ET)

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 26 Analyst Ratings

Based on 26 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 3 have given a sell rating, 7 have given a hold rating, and 16 have given a buy rating for VRTX.

Consensus Price Target

$485.91
2.48% Upside

High Forecast	$600.00
Average Forecast	$485.91
Low Forecast	$325.00

According to the 26 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $485.91. The highest price target for VRTX is $600.00, while the lowest price target for VRTX is $325.00. The average price target represents a forecasted upside of 2.48% from the current price of $474.16.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$485.91	$485.91	$443.55	$367.04
Forecasted Upside	2.48% Upside	5.13% Upside	7.56% Upside	9.16% Upside

War on Elon Escalates… (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	2.48% Upside	1,006.89% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/5/2024	HC Wainwright 2 of 5 stars		Boost Target	Buy ➝ Buy	$500.00 ➝ $600.00	+25.81%
8/5/2024	Oppenheimer 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$500.00 ➝ $550.00	+15.31%
8/5/2024	Truist Financial 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$508.00 ➝ $550.00	+16.17%
8/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$505.00 ➝ $510.00	+7.72%
8/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$472.00 ➝ $509.00	+2.94%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $558.00	+13.08%
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad) Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER…
8/2/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$480.00 ➝ $480.00	-4.62%
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$500.00 ➝ $535.00	+7.40%
7/31/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$371.00 ➝ $376.00	-25.90%
7/26/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $500.00	+1.60%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$402.00 ➝ $455.00	-7.66%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/24/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$540.00 ➝ $555.00	+18.41%
6/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$465.00 ➝ $550.00	+15.48%
6/11/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$424.00 ➝ $421.00	-12.89%
5/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$480.00 ➝ $500.00	+11.63%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$498.00 ➝ $466.00	+18.54%
4/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$438.00	+10.17%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$515.00	+23.24%
2/6/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/22/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$373.00	+5.81%
7/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$350.00 ➝ $400.00	+10.55%
6/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/25/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
2/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$374.00 ➝ $365.00	+18.30%
2/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$374.00 ➝ $365.00	+18.30%
12/19/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$340.00	+11.55%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$315.00 ➝ $330.00	+10.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:12 AM ET.

VRTX Forecast - Frequently Asked Questions

What is Vertex Pharmaceuticals' forecast for 2024?: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $485.91, with a high forecast of $600.00 and a low forecast of $325.00.
Should I buy or sell Vertex Pharmaceuticals stock right now?: 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 3 sell ratings, 7 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VRTX shares.
Does Vertex Pharmaceuticals's stock price have much upside?: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 5.13% based on their 12-month stock forecasts.
Has Vertex Pharmaceuticals been downgraded by Wall Street analysts recently?: Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 downgrade by analysts.
What analysts cover Vertex Pharmaceuticals?: Vertex Pharmaceuticals has been rated by research analysts at Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Redburn Atlantic, TD Cowen, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Vertex Pharmaceuticals more than its competitors?: Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.50 while the average consensus rating score for "medical" companies is 2.77. Learn more on how VRTX compares to other companies.